Biofrontera appoints George Jones as chief commercial officer

WOBURN, Massachusetts - Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company with a market capitalization of $9.6 million and revenue growth of 14.28% in the last twelve months, has appointed George Jones as Chief Commercial Officer effective August 25, 2025, the company announced Monday.

Jones, who brings over 25 years of commercial leadership experience in specialty pharmaceuticals and biotech, will oversee sales, marketing, and market access functions, reporting directly to CEO Dr. Hermann Luebbert. According to InvestingPro analysis, the company faces challenges with cash burn, though it maintains a healthy gross profit margin of 53.26%.

The appointment follows Biofrontera’s recent acquisition of all U.S. rights and assets related to Ameluz and RhodoLED from its former parent company Biofrontera AG. Under the new arrangement, the company will pay a monthly Ameluz royalty between 12% and 15%, replacing the previous transfer pricing model that required payments of 25% to 35% of net sales price per tube. While the company reported negative EBITDA of $15.97 million, InvestingPro data shows recent positive momentum in the stock’s performance.

Jones previously served as Chief Operating Officer at UpScriptHealth, where he helped achieve a threefold increase in partnership revenues. His experience includes leadership roles at Currax Pharmaceuticals as Vice President of Global Marketing and Commercial Operations, Pernix Therapeutics as Vice President of Sales and Marketing, and Depomed, Inc. as Senior Director of Marketing.

"George’s proven track record of building high-performing teams, driving sustainable growth, and delivering patient-centric commercial solutions at mid-sized pharmaceutical companies makes him the ideal leader to accelerate Biofrontera’s continued growth," said Dr. Luebbert in the press release.

Biofrontera specializes in photodynamic therapy, commercializing the drug-device combination Ameluz with the RhodoLED lamp series for treating actinic keratosis, pre-cancerous skin lesions that may progress to invasive skin cancers. Get deeper insights into Biofrontera’s financial health and growth potential with InvestingPro, which offers exclusive analysis and 7 additional ProTips for informed investment decisions.

In other recent news, Biofrontera Inc. has announced a favorable restructuring agreement with Biofrontera AG and completed an $11 million financing deal with existing investors. This restructuring will enable Biofrontera Inc. to acquire all U.S. assets related to Ameluz and assume responsibilities for U.S. manufacturing, regulatory, quality management, and pharmacovigilance. Additionally, Biofrontera is engaged in negotiations with Biofrontera AG regarding a potential business combination or adjustments to their existing agreements, which could result in the transfer of certain rights and a reduction in transfer prices for U.S. sales.

Biofrontera Inc. also recently filed a supplement to its Proxy Statement, aiming to clarify information regarding stockholder voting implications. Furthermore, the company has secured a patent for its propylene glycol-free Ameluz formulation, extending its protection until 2043. This new formulation is designed to reduce allergic reactions without affecting treatment efficacy.

In analyst updates, Benchmark has revised its price target for Biofrontera shares to $2.75, down from $7.00, while maintaining a Buy rating. This adjustment follows Biofrontera’s first-quarter revenue report, which showed earnings of $8.6 million, falling short of projections. Despite this, the company remains optimistic about revenue growth, particularly in the fourth quarter, with new labeling expected to enhance Ameluz sales.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.